Eurogentec Acquires License From OGT to Develop Oligo Microarray Business
News Apr 28, 2006
Eurogentec S.A. and Oxford Gene Technology have announced the conclusion of a licensing agreement, wherein Eurogentec has acquired a licence to OGT’s "Southern array patents", the fundamental patents covering the manufacture and use and marketing of oligonucleotide microarrays. The licence will remain valid for the patents’ lifetime.
Commenting on the agreement, Dr. Driss Talibi, DNA Array Product Manager at Eurogentec, said, "We were in contact with OGT at the earliest stage to discuss the successful agreement, which further strengthens our position in the market segment of custom-made oligo-based microarrays."
Jean-Pierre Delwart, CEO at Eurogentec, further added, "The agreement is very important for our genomic oligo business and we believe that this licence will strongly contribute to increase our HTP oligo business."
Dr Mike Evans, Chief Executive of OGT, said, "We are happy to support Eurogentec’s technology by granting this licence."
"We continue to extend our licensing policy whilst expanding our focus on the development of microarray based products and our custom service offering for the life sciences research and diagnostic markets."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019